Wire · opportunities
Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 8 November 2026 · Fusion42 review
Cabaletta Bio reported positive Phase 1/2 clinical data for rese-cel, a targeted cell therapy showing durable, immunomodulator-free improvement across multiple autoimmune diseases including dermatomyositis, lupus nephritis, and systemic sclerosis. The data highlight promising efficacy and a favourable benefit-risk profile through one year, supporting ongoing development and upcoming regulatory submissions.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a new standard for autoimmune therapies with rese-cel's immunomodulator-free one-year durability. Review your development plans now to match this emerging benchmark or risk falling behind in autoimmune treatment innovation.
◆ Coverage
1 source · 8 Nov 2026
◆ Related on Wire
◆ Topics